Lucian R Chirieac Selected Research

Lucian R Chirieac Research Topics

Disease

54	Neoplasms (Cancer) 04/2024 - 04/2005
20	Lung Neoplasms (Lung Cancer) 01/2022 - 06/2006
14	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 02/2007
12	Adenocarcinoma of Lung 07/2014 - 02/2007
11	Mesothelioma 04/2024 - 04/2006
11	Carcinoma (Carcinomatosis) 01/2023 - 03/2005
10	Malignant Mesothelioma 06/2021 - 04/2006
9	Adenocarcinoma 01/2018 - 03/2005
5	Neoplasm Metastasis (Metastasis) 01/2016 - 04/2009
4	Carcinogenesis 04/2009 - 06/2006
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 08/2009
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2010 - 02/2007
2	Margins of Excision 06/2010 - 04/2010
2	Microsatellite Instability 05/2008 - 04/2005
2	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 07/2007 - 05/2007
1	Inflammation (Inflammations) 01/2018
1	Lymphocytosis 01/2018
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Fever (Fevers) 10/2017
1	Retinoblastoma (Glioblastoma, Retinal) 10/2017
1	Hyperuricemia 10/2017
1	Hypotension (Low Blood Pressure) 10/2017
1	Pancytopenia 10/2017
1	Lymphoma (Lymphomas) 12/2013
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2012
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 05/2012
1	Sarcoma (Soft Tissue Sarcoma) 01/2012
1	Genomic Instability 09/2011
1	Lewis Lung Carcinoma 06/2010

Drug/Important Bio-Agent (IBA)

11	ErbB Receptors (EGF Receptor)IBA 07/2014 - 06/2006
9	DNA (Deoxyribonucleic Acid)IBA 02/2018 - 12/2007
8	Phosphotransferases (Kinase)IBA 01/2024 - 06/2006
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2009
6	AsbestosIBA 01/2024 - 12/2013
6	AntibodiesIBA 01/2018 - 05/2009
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2012 - 06/2006
5	Tyrosine Kinase InhibitorsIBA 07/2010 - 07/2007
4	Messenger RNA (mRNA)IBA 01/2021 - 10/2005
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 03/2010
4	ParaffinIBA 01/2013 - 10/2007
3	Anaplastic Lymphoma KinaseIBA 02/2018 - 07/2010
3	Gefitinib (Iressa)FDA Link 05/2012 - 07/2008
2	Neurofibromin 2 (Merlin)IBA 04/2024 - 01/2024
2	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2010
2	B7-H1 AntigenIBA 01/2020 - 01/2019
2	LigandsIBA 01/2019 - 10/2008
2	RNA (Ribonucleic Acid)IBA 02/2018 - 03/2008
2	MucinsIBA 01/2018 - 03/2005
2	1-methyl-1-piperidinomethane sulfonateIBA 05/2013 - 03/2008
2	Bevacizumab (Avastin)FDA Link 05/2012 - 03/2010
2	AZD 6244IBA 03/2012 - 12/2008
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2012 - 04/2010
2	PolymersIBA 01/2012 - 04/2010
2	CollagenIBA 06/2010 - 05/2010
2	Transcription Factors (Transcription Factor)IBA 11/2009 - 12/2007
2	Cisplatin (Platino)FDA LinkGeneric 02/2009 - 04/2006
2	Sirolimus (Rapamycin)FDA Link 01/2009 - 07/2007
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2008 - 05/2007
2	neratinibIBA 07/2007 - 06/2006
2	Cetuximab (Erbitux)FDA Link 02/2007 - 06/2006
1	ChromatinIBA 01/2024
1	Estrogens (Estrogen)FDA Link 02/2021
1	Growth InhibitorsIBA 02/2021
1	claudin 15IBA 01/2021
1	VimentinIBA 01/2021
1	Inosine Monophosphate (IMP)IBA 01/2020
1	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2020
1	Thyroid Nuclear Factor 1IBA 01/2019
1	dinaciclibIBA 10/2017
1	Transaminases (Aminotransferases)IBA 10/2017
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 10/2017
1	TropomyosinIBA 07/2014
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 07/2014
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 07/2014
1	romidepsin (FK228)FDA Link 12/2012
1	Histone Deacetylase InhibitorsIBA 12/2012
1	Histone Deacetylases (Histone Deacetylase)IBA 12/2012
1	Glucose (Dextrose)FDA LinkGeneric 05/2012
1	Retinoblastoma ProteinIBA 05/2012
1	palbociclibIBA 05/2012
1	CrizotinibIBA 05/2012
1	Tumor Biomarkers (Tumor Markers)IBA 05/2012
1	Docetaxel (Taxotere)FDA Link 03/2012
1	SmokeIBA 09/2011
1	hemoglobin P (Hb P)IBA 08/2011
1	Keratins (Keratin)IBA 01/2011
1	Formaldehyde (Formol)FDA Link 08/2010
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 07/2010
1	CarbonatesIBA 06/2010
1	homocamptothecinIBA 06/2010
1	EstersIBA 06/2010

Therapy/Procedure

31	Therapeutics 01/2024 - 04/2005
6	Pneumonectomy (Lung Volume Reduction) 11/2020 - 02/2009
4	Immunotherapy 01/2022 - 01/2017
3	Esophagectomy 01/2007 - 03/2005
2	Neoadjuvant Therapy 11/2011 - 01/2007
1	Drug Therapy (Chemotherapy) 01/2020
1	Radiotherapy 12/2014
1	Investigational Therapies (Experimental Therapy) 01/2012
1	Molecular Targeted Therapy 01/2011